Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study tests the hypothesis that endogenous aldosterone impairs insulin secretion and insulin sensitivity in subjects with primary aldosteronism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans

NCT04461015

Healthy

COMPLETED PHASE3

Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism

NCT04300049

Insulin Sensitivity

COMPLETED EARLY_PHASE1

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

NCT06424106

PreDiabetes

RECRUITING NA

Physiologic Response to Glucagon at Varying Insulin Levels

NCT01483651

Type 1 Diabetes Mellitus

COMPLETED NA

Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion

NCT02010827

Type 2 Diabetes Mellitus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The week of each study period, subjects will be provided a standard 160mmol/d sodium diet for 6-8 days to control for inter-individual sodium intake.

In period 1, subjects will report after 5 days of controlled sodium diet for a hyperglycemic clamp study (to measure insulin secretion). Subjects will continue the study diet, and then return for a hyperinsulinemic-euglycemic clamp study (to measure insulin sensitivity).

After completion of period 1 assessment, subjects will undergo adrenalectomy by our endocrine surgeons or initiate medical treatment, according to routine clinical care.

In period 2, the investigators will repeat the studies in the same manner as period 1, 3 to 12 months after adrenalectomy or initiation of medical treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Aldosteronism

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adrenalectomy

Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism

Adrenalectomy

Intervention Type OTHER

Adrenalectomy for treatment of primary aldosteronism, according to standard of care

Medical Therapy

Subjects will undergo assessment before and after medical treatment of primary aldosteronism

mineralocorticoid receptor antagonist

Intervention Type DRUG

Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adrenalectomy

Adrenalectomy for treatment of primary aldosteronism, according to standard of care

Intervention Type OTHER

mineralocorticoid receptor antagonist

Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

spironolactone eplerenone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ambulatory subjects, 18 to 70 years of age, inclusive
2. For female subjects, the following conditions must be met:

* postmenopausal status for at least 1 year, or
* status-post surgical sterilization, or
* if of childbearing potential, utilization of adequate birth control and willingness to undergo urine beta-hcg testing on every study day.
3. Primary aldosteronism determined by both:

* Biochemical hyperaldosteronism defined as either:

1. Plasma aldosterone ≥15 ng/dL
2. or aldosterone-to-renin ratio of ≥30 if on ACE inhibitor
3. or aldosterone-to-renin ratio of ≥40 in absence of an ACE inhibitor
* Positive suppression test defined as either:

1. failure to suppress aldosterone to \<7ng/dL after intravenous 0.9% saline infusion over 2 hours
2. failure to suppress 24-hour urinary aldosterone excretion to \<12 µcg with simultaneously documented urine sodium excretion \>200 mmol.

Exclusion Criteria

\- Subjects presenting with any of the following will not be included in the study:

1. Previously diagnosed type 1 Diabetes
2. Type II Diabetes, as defined by ADA criteria:

* Hemoglobin A1C ≥6.5%
* Fasting plasma glucose ≥126mg/dl (7.0mmol/l)
* 2-hour 75g oral glucose tolerance test (OGTT) plasma glucose ≥200mg/dl (11.1 mmol/l) d. Current treatment with anti-diabetic medication(s)
3. Impaired renal function \[estimated glomerular filtration rate (eGFR) of \<30ml/min\] as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dl and age in years.
4. Prior allergies to medications used in the study protocol (e.g. L-arginine, potassium chloride, insulin), or to drugs within the same class.
5. Screening plasma potassium \>5.5 mmol/L or sodium \<135 mmol/L
6. Cardiovascular disease such as recent (\<6 months) myocardial infarction, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis or hypertrophic cardiomyopathy
7. Breast-feeding
8. Treatment with anticoagulants
9. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack
10. History or presence of immunological or hematological disorders
11. Diagnosis of asthma requiring use of inhaled beta agonist \>1 time per week
12. Clinically significant gastrointestinal impairment that could interfere with drug absorption
13. Impaired hepatic function \[aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) \>2.0 x upper limit of normal range\]
14. Hematocrit \<35%
15. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with non-steroidal antiinflammatory drugs
16. Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)
17. Treatment with lithium salts
18. History of alcohol or drug abuse
19. Treatment with any investigational drug in the 1 month preceding the study
20. Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study
21. Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No